296 related articles for article (PubMed ID: 24563068)
21. [Quality of life as an independent prognostic factor in advanced non-small-cell lung cancer in general practice].
Nishiyama O; Taniguchi H; Kondoh Y; Kimura T; Kato K; Noma S; Iwaki M; Aso H; Sakamoto K; Shimizu J
Nihon Kokyuki Gakkai Zasshi; 2006 May; 44(5):368-73. PubMed ID: 16780094
[TBL] [Abstract][Full Text] [Related]
22. Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scale.
Cella D
Semin Oncol; 2003 Feb; 30(1 Suppl 1):39-48. PubMed ID: 12644983
[TBL] [Abstract][Full Text] [Related]
23. The quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD): validity and reliability in japanese patients with advanced non-small-cell lung cancer.
Matsumoto T; Ohashi Y; Morita S; Kobayashi K; Shibuya M; Yamaji Y; Eguchi K; Fukuoka M; Nagao K; Nishiwaki Y; Niitani H;
Qual Life Res; 2002 Aug; 11(5):483-93. PubMed ID: 12113395
[TBL] [Abstract][Full Text] [Related]
24. Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801.
Sarna L; Swann S; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Byhardt R; Wasserman T; Movsas B
Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1378-84. PubMed ID: 18501528
[TBL] [Abstract][Full Text] [Related]
25. Trends in endpoint selection and result interpretation in advanced non-small cell lung cancer clinical trials published between 2000 and 2012: A retrospective cohort study.
Fernández-López C; Calleja-Hernández MÁ; Balbino JE; Cabeza-Barrera J; Expósito-Hernández J
Thorac Cancer; 2019 Apr; 10(4):904-908. PubMed ID: 30868737
[TBL] [Abstract][Full Text] [Related]
26. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer.
Brown J; Thorpe H; Napp V; Fairlamb DJ; Gower NH; Milroy R; Parmar MK; Rudd RM; Spiro SG; Stephens RJ; Waller D; West P; Peake MD
J Clin Oncol; 2005 Oct; 23(30):7417-27. PubMed ID: 16157935
[TBL] [Abstract][Full Text] [Related]
27. Trends and predictors of Quality of Life in lung cancer survivors.
Bade BC; Zhao J; Li F; Tanoue L; Lazowski H; Alfano CM; Silvestri GA; Irwin ML
Lung Cancer; 2024 May; 191():107793. PubMed ID: 38640687
[TBL] [Abstract][Full Text] [Related]
28. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
29. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
30. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline.
Noble J; Ellis PM; Mackay JA; Evans WK;
J Thorac Oncol; 2006 Nov; 1(9):1042-58. PubMed ID: 17409993
[TBL] [Abstract][Full Text] [Related]
31. Treatment Satisfaction of Patients With Advanced Non-Small-cell Lung Cancer Receiving Platinum-based Chemotherapy: Results From a Prospective Cohort Study (PERSONAL).
Visser S; de Mol M; Cheung K; van Toor JJ; van Walree NC; Stricker BH; Den Oudsten BL; Aerts JGJV
Clin Lung Cancer; 2018 Jul; 19(4):e503-e516. PubMed ID: 29705017
[TBL] [Abstract][Full Text] [Related]
32. [Impact of erlotinib treatment on symptoms and quality of life in patients with advanced non-small-cell lung cancer].
Zhou SW; Ren SX; Yan LH; Zhang L; Zhou CC
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):469-72. PubMed ID: 19024526
[TBL] [Abstract][Full Text] [Related]
33. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Bezjak A; Tu D; Seymour L; Clark G; Trajkovic A; Zukin M; Ayoub J; Lago S; de Albuquerque Ribeiro R; Gerogianni A; Cyjon A; Noble J; Laberge F; Chan RT; Fenton D; von Pawel J; Reck M; Shepherd FA;
J Clin Oncol; 2006 Aug; 24(24):3831-7. PubMed ID: 16921034
[TBL] [Abstract][Full Text] [Related]
34. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Chen Y; Zhou J; Wang D
Lung Cancer; 2018 Aug; 122():32-37. PubMed ID: 30032842
[TBL] [Abstract][Full Text] [Related]
35. Elemene injection as adjunctive treatment to platinum-based chemotherapy in patients with stage III/IV non-small cell lung cancer: A meta-analysis following the PRISMA guidelines.
Wang X; Liu Z; Sui X; Wu Q; Wang J; Xu C
Phytomedicine; 2019 Jun; 59():152787. PubMed ID: 31005810
[TBL] [Abstract][Full Text] [Related]
36. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.
Novello S; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Barrueco J; Gaschler-Markefski B; Griebsch I; Palmer M; Reck M;
Eur J Cancer; 2015 Feb; 51(3):317-26. PubMed ID: 25534294
[TBL] [Abstract][Full Text] [Related]
37. The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials.
Wheatley-Price P; Le Maître A; Ding K; Leighl N; Hirsh V; Seymour L; Bezjak A; Shepherd FA;
J Thorac Oncol; 2010 May; 5(5):640-8. PubMed ID: 20354457
[TBL] [Abstract][Full Text] [Related]
38. Staged versus conventional nursing for patients receiving chemotherapy for advanced non-small cell lung cancer: a before and after study.
Zhu L; Chen L; Kan H; Cai P
Ann Palliat Med; 2021 Jan; 10(1):250-257. PubMed ID: 33474963
[TBL] [Abstract][Full Text] [Related]
39. Quality of Life in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Palliative Chemotherapy.
Daroszewski C; Stasiewicz M; Jaźwińska-Tarnawska E; Rachwalik A; Mura E; Luboch-Kowal J; Dryś A; Bogucki ZA; Brzecka A
Adv Exp Med Biol; 2019; 1160():11-18. PubMed ID: 30825114
[TBL] [Abstract][Full Text] [Related]
40. The association of depressive symptoms, personality traits, and sociodemographic factors with health-related quality of life and quality of life in patients with advanced-stage lung cancer: an observational multi-center cohort study.
de Mol M; Visser S; Aerts J; Lodder P; van Walree N; Belderbos H; den Oudsten B
BMC Cancer; 2020 May; 20(1):431. PubMed ID: 32423432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
